Novartis (NVS) said multiple US real-world studies reinforced earlier use of Pluvicto before chemotherapy in metastatic castration-resistant prostate cancer. Real-world use of Pluvicto resulted in a median progression-free survival of 13.5 months in chemo-naïve patients with metastatic castration-resistant prostate cancer. Also, real-world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead of multiple ARPIs.
The company said real-world findings are consistent with PSMAfore, which supported the approval of Pluvicto for patients with PSMA-positive mCRPC who have been treated with an ARPI and are considered appropriate to delay taxane-based chemotherapy.
In pre-market trading on NYSE, Novartis shares are up 1.03 percent to $166.40.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.